Bli medlem
Bli medlem

Du är här

2022-11-11

Camurus AB: Camurus to present at Jefferies 2022 Healthcare Conference London

Lund, Sweden - 11 November 2022 - Camurus (Nasdaq Stockholm; CAMX) announces that Fredrik Tiberg, President and CEO, will present at the Jefferies 2022 Healthcare Conference in London on 16 November 10:55 am local time (BST). An audiocast of the presentation can be accessed via https://wsw.com/webcast/jeff255/camx.st/2240946 (https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwsw.com%2Fwebcast%2Fjeff255%2Fcamx.st%2F2240946&data=05%7C01%7CAnna.Bolin%40camurus.com%7C62ebab47e07f4d75610808dac0c41d37%7C4548154025e04e818dd161166638454e%7C0%7C0%7C638034245772396996%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=OlHjE9Glydy5dTtxVRVOxQefgN2cvyHYK1Fqk8uMXU0%3D&reserved=0).

For more information
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com

About Camurus
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal[®] drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.

This information was submitted for publication at 8:00 am CET on 11 November 2022.

Författare Cision